Autonomix Medical (AMIX) Registration filing summary

Company overview and business model

• Development-stage medical device company focused on innovative catheter-based technologies for sensing and treating nervous system disorders, initially targeting pain management in pancreatic cancer patients.

• Proprietary microchip-enabled sensing array offers 3,000x greater sensitivity than leading competitors, enabling precise neural signal detection and targeted ablation.

• Platform technology has potential applications in chronic pain, hypertension, cardiovascular disease, and other nerve-related disorders.

• Commercialization strategy centers on single-use disposable catheters for hospital labs, with future expansion into broader diagnostic and therapeutic markets.

Financial performance and metrics

• As of June 30, 2024: accumulated deficit of $41.7 million, negative cash flows from operations of $1.9 million, and working capital of $6.3 million.

• Net loss for the year ended March 31, 2024 was $15.4 million, up from $2.0 million in the prior year, driven by increased R&D and G&A expenses.

• Cash and cash equivalents were $6.8 million as of June 30, 2024; estimated to fund operations into but not beyond Q2 2025.

• No revenue generated to date; company remains pre-commercial and dependent on external financing.

Use of proceeds and capital allocation

• Estimated net proceeds of $9.0 million from the offering, primarily allocated to clinical trials, R&D, intellectual property development, and working capital.

• Additional financing of approximately $40 million will be required to fund operations through initial commercial launch.

• Management has broad discretion over use of proceeds; funds not immediately deployed will be invested in short-term instruments.